CJC-1295 (no DAC): GHRH Analogue Pharmacology and a Naming Problem

The naming problem, stated plainly

Jetté et al. (Endocrinology, 2005) identified CJC-1295 as a long-lasting GRF analogue. The mechanism in that paper is a drug affinity complex, the DAC, which forms a covalent bond with circulating albumin and extends half-life to the order of days.

Remove the DAC and you remove that mechanism. What remains is a tetrasubstituted GHRH(1-29) analogue whose substitutions confer resistance to dipeptidyl peptidase-4 cleavage but which does not bind albumin, giving a duration measured in minutes to hours rather than days.

Both are called CJC-1295 in common usage. They are not interchangeable, and a paper about one is not evidence about the other. Any reference to the 2005 half-life data as applying to the no-DAC form is a straightforward misreading.

GHRH receptor pharmacology

GHRH acts on the GHRH receptor, a class B G protein-coupled receptor on anterior pituitary somatotrophs, raising cAMP and stimulating synthesis and pulsatile release of growth hormone. Because release remains pulsatile and subject to somatostatin opposition, GHRH analogues produce a fundamentally different release profile from exogenous growth hormone.

Grossman et al. (Clin Endocrinol Metab, 1986) remains a useful entry point to the underlying GHRH physiology. Esposito et al. (Adv Drug Deliv Rev, 2003) cover PEGylation approaches to extending GRF analogue duration, which is the engineering problem the DAC was designed to solve.

What the recent literature is actually about

A substantial share of indexed work on this compound class is analytical: Memdouh et al. (Drug Test Anal, 2021) on detecting synthetic GHRH analogues, Coppieters et al. (J Pharm Biomed Anal, 2022) on urine detection at low picogram concentrations, Thomas et al. (Anal Sci Adv, 2022) on doping control blood samples.

A separate and unrelated strand concerns GHRH antagonists in oncology, including Gesmundo et al. (Int J Mol Sci, 2025) on radiosensitivity in lung cancer cells. Antagonist work is not evidence about an agonist and should not be cited as though it were.